Terran Biosciences Inc.
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
0
Ending by 2030
Nov 2038
Next term end
When these terms end
Held patents by the year their term ends
20262027202820292030203120322033203420352036203720382039204020412042204320442045
Fee deadlines
Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
- 1 fee due Feb 15, 2027The maintenance fee for Combination product for the treatment of neurological and/or psychiatric disorders (US 11,723,894) comes due Feb 15, 2027. Unpaid by Aug 16, 2027, it lapses early.
- 1 fee due Jun 26, 2027The maintenance fee for Psilocybin and O-acetylpsilocin, salts and solid state forms thereof (US 11,851,452) comes due Jun 26, 2027. Unpaid by Dec 27, 2027, it lapses early.
- 1 fee due Jul 9, 2027The maintenance fee for N,n-Dimethyltryptamine and Related Psychedelics and Uses Thereof (US 11,866,408) comes due Jul 9, 2027. Unpaid by Jan 10, 2028, it lapses early.
- 1 fee due Aug 20, 2027The maintenance fee for Solid forms of tabernanthalog monofumarate salt for treating neurological disorders and/or psychiatric disorders (US 11,905,295) comes due Aug 20, 2027. Unpaid by Feb 22, 2028, it lapses early.
- 2 fees due Oct 2 to 16, 2027 · next Oct 2
Recent changes
- 1 of the patents on this record was granted since Aug 18, 2026
Patents held now
Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 11,723,894 | Combination product for the treatment of neurological and/or psychiatric disorders In force · From the USPTO record | In force | From the USPTO record | |
| US 11,866,408 | N,n-Dimethyltryptamine and Related Psychedelics and Uses Thereof In force · Medium confidence | In force | Medium confidence | |
| US 12,780,784 | N,n-Dimethyltryptamine and Related Psychedelics and Uses Thereof In force · Medium confidence | In force | Medium confidence | |
| US 12,234,216 | Isotopologues salts, crystalline forms, stereoisomers, of methylone and ethylone and methods of use thereof In force · From the USPTO record | In force | From the USPTO record | |
| US 11,958,821 | Phenethylamine compounds salts, polymorphic forms and methods of use thereof In force · From the USPTO record | In force | From the USPTO record | |
| US 12,577,222 | Phenethylamine Compounds Salts, Polymorphic Forms and Methods of Use Thereof In force · Medium confidence | In force | Medium confidence | |
| US 11,851,452 | Psilocybin and O-acetylpsilocin, salts and solid state forms thereof In force · From the USPTO record | In force | From the USPTO record | |
| US 11,945,832 | Psilocybin and O-acetylpsilocin, salts and solid state forms thereof In force · From the USPTO record | In force | From the USPTO record | |
| US 12,435,036 | Salts and Solid Forms of (R)-1-(5-Methoxy-1H-INDOL-1-YL)-N,N-DIMETHYLPROPAN-2-Amine In force · High confidence | In force | High confidence | |
| US 11,905,295 | Solid forms of tabernanthalog monofumarate salt for treating neurological disorders and/or psychiatric disorders In force · From the USPTO record | In force | From the USPTO record |
Sources and methods
Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand.
How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
Published applications
US patent applications published under this name that have not become patents. An application is published about eighteen months after its earliest filing; one that has not been published is in no public record.
2 pending · 18 abandoned · 16 no status recorded